Alterity Therapeutics (NASDAQ:ATHE) Given New $3.00 Price Target at The Goldman Sachs Group

Alterity Therapeutics (NASDAQ:ATHEGet Rating) had its target price decreased by equities researchers at The Goldman Sachs Group from $11.00 to $3.00 in a research report issued on Thursday, Stock Target Advisor reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 376.19% from the company’s current price.

Shares of ATHE traded up $0.02 during trading hours on Thursday, hitting $0.63. 100 shares of the stock were exchanged, compared to its average volume of 46,897. The stock’s 50-day moving average price is $0.70 and its two-hundred day moving average price is $0.78. Alterity Therapeutics has a 12-month low of $0.58 and a 12-month high of $2.75.

A hedge fund recently bought a new stake in Alterity Therapeutics stock. Envestnet Asset Management Inc. purchased a new position in shares of Alterity Therapeutics Limited (NASDAQ:ATHEGet Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 82,386 shares of the company’s stock, valued at approximately $59,000. Envestnet Asset Management Inc. owned 0.36% of Alterity Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 3.33% of the company’s stock.

About Alterity Therapeutics (Get Rating)

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.

Read More

Stock Target Advisor logo

Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.